| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/18/2009 | CA2708611A1 Composition of aqueous buffer solution for the treatment of cellular environment and ion channels and methods for using same |
| 06/18/2009 | CA2708606A1 Methods of treating hematologic cancers |
| 06/18/2009 | CA2708570A1 Organic compounds |
| 06/18/2009 | CA2708364A1 Carboxamide compounds and their use as chemokine receptor agonists |
| 06/18/2009 | CA2708352A1 Anti-inflammatory compositions and combinations |
| 06/18/2009 | CA2708343A1 Method for increasing immunoreactivity |
| 06/18/2009 | CA2708303A1 Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
| 06/18/2009 | CA2708300A1 Gamma secretase modulators |
| 06/18/2009 | CA2708264A1 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
| 06/18/2009 | CA2708262A1 Methods and compositions for treating liquid tumors |
| 06/18/2009 | CA2708241A1 Solid forms of 1-ethyl-3-(5-(5-fluoropyridin-3-yl)-7-(pyrimidin-2-yl)-1h-benzo[d]imidazol-2-yl)urea |
| 06/18/2009 | CA2708234A1 Aqueous loxoprofen-containing patches |
| 06/18/2009 | CA2708233A1 Tape preparation comprising etodolac in ionic liquid form |
| 06/18/2009 | CA2708159A1 Pharmaceutical formulation comprising ezetimibe |
| 06/18/2009 | CA2708151A1 Gamma secretase modulators |
| 06/18/2009 | CA2708150A1 Fluorinated tripeptide hcv serine protease inhibitors |
| 06/18/2009 | CA2708149A1 Combinations of therapeutic agents for treating cancer |
| 06/18/2009 | CA2708146A1 Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| 06/18/2009 | CA2708137A1 Use |
| 06/18/2009 | CA2708083A1 Organic compounds |
| 06/18/2009 | CA2707981A1 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists |
| 06/18/2009 | CA2707969A1 Micronized opioid compositions, formulations and dosage forms and methods of making same |
| 06/18/2009 | CA2707857A1 Organic compounds |
| 06/18/2009 | CA2707681A1 Pharmaceutical preparation for treating demyelinating diseases of the nervous system; preparation promoting restoration of the myelin sheath of nerve fibers; and a method for treating demyelinating diseases of the nervous system |
| 06/18/2009 | CA2707593A1 Clofarabine phospholipid derivatives |
| 06/18/2009 | CA2707492A1 Gamma secretase modulators |
| 06/18/2009 | CA2707491A1 Inhibitors of janus kinases |
| 06/18/2009 | CA2707313A1 Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 06/18/2009 | CA2707305A1 Glycine transporter-1 inhibitors |
| 06/18/2009 | CA2707105A1 Inhibitors of stearoyl-coa desaturase |
| 06/18/2009 | CA2707047A1 Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| 06/18/2009 | CA2706834A1 Thiophene derivatives as agonists of s1p1/edg1 |
| 06/18/2009 | CA2706813A1 Novel 2-arylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals |
| 06/18/2009 | CA2706811A1 Novel 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals |
| 06/18/2009 | CA2706806A1 Novel 2-substituted tiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals |
| 06/18/2009 | CA2706789A1 Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree |
| 06/18/2009 | CA2706679A1 Novel compounds 010 |
| 06/18/2009 | CA2706658A1 Methods useful for the treatment of pain, arthritic conditions or inflammation associated with a chronic condition |
| 06/18/2009 | CA2705921A1 Dual-acting benzoimidazole derivatives and their use as antihypertensive agents |
| 06/18/2009 | CA2705467A1 Compounds and methods for the treatment of cancer |
| 06/18/2009 | CA2700599A1 Pyrazolo-pyrazines derivatives used as g protein inhibitors |
| 06/18/2009 | CA2700559A1 Nicotinamide derivatives, preparation thereof and therapeutic use thereof |
| 06/18/2009 | CA2699733A1 6,11-bridged biaryl macrolides |
| 06/17/2009 | EP2071036A2 Methods for identifying RNA-binding compounds |
| 06/17/2009 | EP2071030A2 Oligoribonucleotide or peptide nucleic acid which inhibits action of hepatitis C virus |
| 06/17/2009 | EP2070971A1 Compound of resorcinol derivative with polymer |
| 06/17/2009 | EP2070944A1 Specific binding agents of human angiopoietin-2 |
| 06/17/2009 | EP2070939A1 Modulators of pharmacological agents |
| 06/17/2009 | EP2070938A1 Clofarabine dietherphospholipid derivatives |
| 06/17/2009 | EP2070933A1 Tricyclic triazolic compounds |
| 06/17/2009 | EP2070932A1 Pyrazolotriazines |
| 06/17/2009 | EP2070930A1 Polycycloalkylpurines as adenosine receptor antagonists |
| 06/17/2009 | EP2070928A1 7-azaindol-3-ylacrylamides active as kinase inhibitors |
| 06/17/2009 | EP2070927A1 Fused heterocyclic derivative |
| 06/17/2009 | EP2070926A1 13,13a-DIHYDROBERBERINE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITION AND USE |
| 06/17/2009 | EP2070925A1 New 2-substituted tiazol-4-carboxylic acid derivatives, their manufacture and use as medicine |
| 06/17/2009 | EP2070924A1 New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine |
| 06/17/2009 | EP2070922A1 Azabicyclo(3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors |
| 06/17/2009 | EP2070921A1 Indolylmaleimide derivatives as protein kinase c inhibitors |
| 06/17/2009 | EP2070920A1 Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels |
| 06/17/2009 | EP2070919A1 Spiroquinone compound and pharmaceutical composition |
| 06/17/2009 | EP2070916A1 2-Arylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine |
| 06/17/2009 | EP2070914A1 New antagonist derivatives of the vitronectin receiver, method for preparing same, application of same as medicine and pharmaceutical compositions containing them |
| 06/17/2009 | EP2070913A1 Ester derivatives as phosphodiesterase inhibitors |
| 06/17/2009 | EP2070911A2 Stabilized 1Alpha-Hydroxy vitamin D |
| 06/17/2009 | EP2070909A1 Non-steroidal progesterone receptor modulators |
| 06/17/2009 | EP2070908A1 Compound having benzamide skeleton and cyclooxygenase (cox-1)-selective inhibitory activity |
| 06/17/2009 | EP2070550A1 Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases |
| 06/17/2009 | EP2070546A1 Preventives/remedies for cancer |
| 06/17/2009 | EP2070540A1 Drug composition for treating 2 type diabetes and its chronicity neopathy |
| 06/17/2009 | EP2070538A1 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
| 06/17/2009 | EP2070537A1 Crystalline polymorphs of topotecan hydrochloride and methods for the preparation thereof |
| 06/17/2009 | EP2070536A1 Pharmaceutical composition comprising phenylamidine derivative and method of using the pharmaceutical composition in combination with antifungal agent |
| 06/17/2009 | EP2070535A1 Drugs for relieving carbonyl stress and peritoneal dialysates |
| 06/17/2009 | EP2070534A2 Cyclopropyl and cyclobutyl epothilone analogs |
| 06/17/2009 | EP2070533A1 Use of a compound derived from P-hydroxyphenyl propionic acid for the treatment of psoriasis |
| 06/17/2009 | EP2070532A1 O/w/o emulsion containing lignan compound, and composition comprising the same |
| 06/17/2009 | EP2070531A1 Pharmaceutical preparation containing histamine H2-receptor antagonists having wound healing activity at low doses |
| 06/17/2009 | EP2070530A1 Treatment of diseases associated with the use of antibiotics |
| 06/17/2009 | EP2070529A1 Medical use of 3-(2,2,2-trimethylhydrazinium) propionate orotate |
| 06/17/2009 | EP2070528A1 Method for absorbing odours |
| 06/17/2009 | EP2070527A1 Inhibitors of fungal biofilm-formation |
| 06/17/2009 | EP2070526A1 "Methods for treatment of Parkinson's disease" |
| 06/17/2009 | EP2070525A1 Compositions comprising Magnolol and/or Honokiol and chondroitin and use thereof for the treatment, co-treatment or prevention of inflammatory disorders |
| 06/17/2009 | EP2070524A1 Compositions comprising Magnolol and/or Honokiol and glucosamine and use thereof for the treatment, co-treatment or prevention of inflammatory disorders |
| 06/17/2009 | EP2070523A1 Composition comprising Magnolol and Honokiol in synergistic amount |
| 06/17/2009 | EP2070522A1 Compounds for preventing and treating plasmodium infections. |
| 06/17/2009 | EP2070521A1 Surface-modified nanoparticles |
| 06/17/2009 | EP2070520A1 Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media |
| 06/17/2009 | EP2070519A1 Preparation for the prevention and/or treatment of dementia syndromes |
| 06/17/2009 | EP2070517A2 Pharmaceutical composition and method for treating hypogonadism |
| 06/17/2009 | EP2070513A1 Antioxidant combinations with 6,7 disubstituted 2.2-dialkylchromanes or chromenes |
| 06/17/2009 | EP2069795A1 Synergistic treatment of cells that express epha2 and erbb2 |
| 06/17/2009 | EP2069501A2 Rna interference against wrap53 to treat hyperproliferative diseases |
| 06/17/2009 | EP2069500A2 Compositions comprising a sirna and lipidic 4,5-disubstituted 2-deoxystreptamine ring aminoglycoside derivatives and uses thereof |
| 06/17/2009 | EP2069498A1 Inhibitory polynucleotide compositions and methods for treating cancer |
| 06/17/2009 | EP2069390A2 Opsin stabilizing compounds and methods of use |
| 06/17/2009 | EP2069383A2 Synthetic bile acid composition, method, and preparation |
| 06/17/2009 | EP2069380A2 Rnai modulation of scap and therapeutic uses thereof |
| 06/17/2009 | EP2069377A2 Methods and compositions for the treatment of skin diseases and disorders |